A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Recruiting now · Phase 2
Conditions studied: Non-Small Cell Lung Cancer
In brief
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in the blood at a given time? * Does the body make antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)?
Key facts
- Study ID
- NCT06465329
- Run by
- Regeneron Pharmaceuticals
- People needed
- 120
- Starts
- 2024-11-18
- Expected to finish
- 2030-05-02
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Irvine — Orange, California, United States (enrolling)
- Orchard Healthcare Research Inc. — Skokie, Illinois, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Detroit Clinical Research Center — Farmington Hills, Michigan, United States (enrolling)
- Morristown Medical Center — Morristown, New Jersey, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- Oncology Hematology Care Clinical Trials LLC — Cincinnati, Ohio, United States (enrolling)
- Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- University Of Nebraska Medical Center — Portland, Oregon, United States (enrolling)
- Lifespan Cancer Institute — Providence, Rhode Island, United States (enrolling)
- Prairie Lakes Healthcare System — Watertown, South Dakota, United States (enrolling)
- University of Tennessee Medical Center — Knoxville, Tennessee, United States (enrolling)
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee, United States (enrolling)
- Tennessee Oncology — Nashville, Tennessee, United States (enrolling)
- BRCC/Oncology & Hematology Associates of SW Virginia — Blacksburg, Virginia, United States (enrolling)
- Oncology Clinical Research Center — Cachoeiro de Itapemirim, Espírito Santo, Brazil (enrolling)
- Instituto Mario Penna — Belo Horizonte, Minas Gerais, Brazil (enrolling)
- Instituto Sul Mineiro De Oncologia LTDA — Pouso Alegre, Minas Gerais, Brazil (enrolling)
- Instituto de Medicina Integral Professor Fernando Figueira — Recife, Pernambuco, Brazil (enrolling)
- Liga Norte Riograndense Contra o Cancer — Natal, Rio Grande do Norte, Brazil (enrolling)
- Hospital Mae de Deus Integrated Oncology Center — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- Hospital Sao Lucas da PUCRS — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- Ynova Pesquisa Clinica — Florianópolis, Santa Catarina, Brazil (enrolling)
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto — São José do Rio Preto, São Paulo, Brazil (enrolling)
- Unimed Sorocaba — Sorocaba, São Paulo, Brazil (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.